Cargando…

Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX

The insulin-like growth factor (IGF) axis plays a crucial role in proliferation, differentiation, migration, angiogenesis, and apoptosis. The present study evaluated the associations between IGF axis single-nucleotide polymorphisms (SNPs) and clinical outcomes in advanced gastric cancer (AGC) patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Sung Yong, Shin, Aesun, Kim, Seong-Geun, Hwang, Jung-Ah, Hong, Seung Hyun, Lee, Yeon-Su, Kwon, Hyuk-Chan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058750/ https://www.ncbi.nlm.nih.gov/pubmed/27144430 http://dx.doi.org/10.18632/oncotarget.9100

Ejemplares similares

The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer
por: Oh, Sung Yong, et al.
Publicado: (2013)

Association Study between Folate Pathway Gene Single Nucleotide Polymorphisms and Gastric Cancer in Koreans
por: Yoo, Jae-Young, et al.
Publicado: (2012)

A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis
por: Lee, Dong Hyun, et al.
Publicado: (2011)

Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
por: Lee, Suee, et al.
Publicado: (2013)

Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
por: Keam, Bhumsuk, et al.
Publicado: (2008)

Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
por: Jeon, Eun Kyoung, et al.
Publicado: (2011)

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting
por: Kim, Chee Young, et al.
Publicado: (2015)

Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX
por: Kim, Mi-Jung, et al.
Publicado: (2016)

Adipokines, insulin-like growth factor binding protein-3 levels, and insulin sensitivity in women with polycystic ovary syndrome
por: Lee, Hyejin, et al.
Publicado: (2013)

Polymorphisms in the Insulin-Like Growth Factor Axis Are Associated with Gastrointestinal Cancer
por: Ong, Jennie, et al.
Publicado: (2014)

Two postoperative chemotherapies for gastric cancer: FOLFOX4 vs. TPF
por: Xie, Honghu, et al.
Publicado: (2019)

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
por: Lee, Jii Bum, et al.
Publicado: (2020)

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
por: Han, S-W, et al.
Publicado: (2009)

Association between CASR Polymorphisms, Calcium Intake, and Colorectal Cancer Risk
por: Kim, Kyee-Zu, et al.
Publicado: (2013)

Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer
por: Li, Zi-Yu, et al.
Publicado: (2011)

FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer
por: CHEN, WENJUN, et al.
Publicado: (2014)

Effect of FOLFOX4 combined with Brucea javanica emulsion on VEGF in patients with gastric cancer
por: Chen, Zheng, et al.
Publicado: (2018)

Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment
por: Lee, Nam Hee, et al.
Publicado: (2016)

Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer
por: Zhao, Shen, et al.
Publicado: (2022)

Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer
por: Kim, Do-Kyong, et al.
Publicado: (2009)

Stem Cell Properties of Gastric Cancer Stem-Like Cells under Stress Conditions Are Regulated via the c-Fos/UCH-L3/β-Catenin Axis
por: Lee, Jae Hyeong, et al.
Publicado: (2023)

Comparison the Incidence and Severity of Side Effects Profile Of FOLFOX and DCF Regimens in Gastric Cancer Patients
por: Salehifar, Ebrahim, et al.
Publicado: (2019)

The Comparison of mDCF and mFOLFOX-6 as First-Line Treatment in Metastatic Gastric Cancer
por: Acikgoz, Yusuf, et al.
Publicado: (2021)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Changes in Body Composition during Adjuvant FOLFOX Chemotherapy and Overall Survival in Non-Metastatic Colon Cancer
por: Chung, Eric, et al.
Publicado: (2019)

Effects of the Insulin-like Growth Factor Pathway on the Regulation of Mammary Gland Development
por: Ha, Woo Tae, et al.
Publicado: (2016)

Gastric Cancer Epidemiology in Korea
por: Shin, Aesun, et al.
Publicado: (2011)

T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy
por: An, Min Sung, et al.
Publicado: (2015)

Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer
por: Liu, Mengyao, et al.
Publicado: (2018)

Folfox encephalopathy: A rare case series
por: Batra, Ullas, et al.
Publicado: (2017)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
por: Jafari, Abdosaleh, et al.
Publicado: (2023)

Insulin-Like Factor 3 and the HPG Axis in the Male
por: Ivell, Richard, et al.
Publicado: (2014)

Relationship between growth velocity and change of levels of insulin-like growth factor-1, insulin-like growth factor binding protein-3 and, IGFBP-3 promoter polymorphism during GnRH agonist treatment
por: Park, Jun-Hong, et al.
Publicado: (2020)

Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients
por: Lee, Dae-Won, et al.
Publicado: (2015)

Plasma Biomarkers of Insulin and the Insulin-like Growth Factor Axis, and Risk of Colorectal Adenoma and Serrated Polyp
por: Hang, Dong, et al.
Publicado: (2019)

Insulin-like growth factor axis in pregnancies affected by fetal growth disorders
por: Nawathe, Aamod R., et al.
Publicado: (2016)

Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX-4 chemotherapy
por: Han, Song-Hee, et al.
Publicado: (2019)

The efficacy and adverse reactions of DCF and FOLFOXs regimens for patients with advanced gastric cancer in China: a meta-analysis
por: Chen, Minxue, et al.
Publicado: (2020)

Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report
por: Seo, Yu Ri, et al.
Publicado: (2010)

Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei
por: Hiraide, Sakura, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_id950h1qbmf893b0l8a4ts09l8